This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

About

Efficacy

Safety & Tolerability

Real World Experience

Support & Resources

Information on how to access XELJANZ®▼ (tofacitinib citrate) prescribing information and adverse event reporting can be found at the bottom of the page.

XELJANZ (tofacitinib citrate): JAK Inhibitor​​​​​​​

​​​​​​​XELJANZ (tofacitinib citrate) is the first JAK inhibitor licensed for use in the treatment of Rheumatoid Arthritis (RA), Ulcerative Colitis (UC) and Psoriatic Arthritis (PsA).1
Please select the most relevant therapeutic area below for dedicated resources and information relating to the efficacy, safety and usage of XELJANZ.

Rheumatoid Arthritis​​​​​​​​​​​​​​​​​​​​

Find the information you need to support your RA patient here.

Visit RA Efficacy

Psoriatic Arthritis

Find the information you need to support your PsA patient here.

This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit PsA Efficacy

Ulcerative Colitis

Find the information you need to support your UC patient here.

Visit UC Efficacy

XELJANZ in action

If you are new to XELJANZ, this short video contains useful information on how XELJANZ works.

Mode of action

Safety & Tolerability

Please click here for an overview of the safety profile of XELJANZ across all licensed indications.

Learn more

Announcement Title

XELJANZ Risk Minimisation Programme (RMP) materials, including a Patient Alert Card, Prescriber Checklists and a Prescriber Brochure are available from https://www.medicines.org.uk/emc/. Patients treated with XELJANZ should be given the Patient Alert Card.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?